Progress in intra-articular therapy

Published

Journal Article (Review)

Diarthrodial joints are well suited to intra-articular injection, and the local delivery of therapeutics in this fashion brings several potential advantages to the treatment of a wide range of arthropathies. Possible benefits over systemic delivery include increased bioavailability, reduced systemic exposure, fewer adverse events, and lower total drug costs. Nevertheless, intra-articular therapy is challenging because of the rapid egress of injected materials from the joint space; this elimination is true of both small molecules, which exit via synovial capillaries, and of macromolecules, which are cleared by the lymphatic system. In general, soluble materials have an intra-articular dwell time measured only in hours. Corticosteroids and hyaluronate preparations constitute the mainstay of FDA-approved intra-articular therapeutics. Recombinant proteins, autologous blood products and analgesics have also found clinical use via intra-articular delivery. Several alternative approaches, such as local delivery of cell and gene therapy, as well as the use of microparticles, liposomes, and modified drugs, are in various stages of preclinical development. © 2014 Macmillan Publishers Limited. All rights reserved.

Full Text

Duke Authors

Cited Authors

  • Evans, CH; Kraus, VB; Setton, LA

Published Date

  • January 1, 2014

Published In

Volume / Issue

  • 10 / 1

Start / End Page

  • 11 - 22

Electronic International Standard Serial Number (EISSN)

  • 1759-4804

International Standard Serial Number (ISSN)

  • 1759-4790

Digital Object Identifier (DOI)

  • 10.1038/nrrheum.2013.159

Citation Source

  • Scopus